MIM
VTGN icon

Monashee Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

Monashee Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,233
Closed -$495K – 375
2021
Q2 		$495K Buy
+5,233
New +$388K 0.06% 239
2021
Q1 		– Sell
-9,722
Closed -$566K – 433
2020
Q4 		$566K Buy
+9,722
New +$248K 0.07% 185

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Monashee Investment Management's VTGN Position: Q3 2021 in Review

Monashee Investment Management sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 5,233 shares — an estimated $495K sold.

Monashee Investment Management first reported a position in VTGN in Q4 2020 and held it in 2 quarters. The position peaked at $566K in Q4 2020. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

  • Monashee Investment Management reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Monashee Investment Management sold 5,233 VistaGen Therapeutics shares in Q3 2021, an estimated $495K.
  • Monashee Investment Management first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 2 quarters.
  • Monashee Investment Management's VistaGen Therapeutics position peaked at $566K in Q4 2020.
  • 104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on Monashee Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.